AU2023381502A1 - Crystal of substituted piperazine derivative and preparation method therefor - Google Patents

Crystal of substituted piperazine derivative and preparation method therefor Download PDF

Info

Publication number
AU2023381502A1
AU2023381502A1 AU2023381502A AU2023381502A AU2023381502A1 AU 2023381502 A1 AU2023381502 A1 AU 2023381502A1 AU 2023381502 A AU2023381502 A AU 2023381502A AU 2023381502 A AU2023381502 A AU 2023381502A AU 2023381502 A1 AU2023381502 A1 AU 2023381502A1
Authority
AU
Australia
Prior art keywords
crystalline form
ray powder
powder diffraction
solvent
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023381502A
Other languages
English (en)
Inventor
Xin Cao
Hongzhu CHU
Zhaojun Liu
Yi Sun
Yonggang Wei
Yuqin ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangbaida Sichuan Biotechnology Co Ltd
Original Assignee
Kangbaida Sichuan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangbaida Sichuan Biotechnology Co Ltd filed Critical Kangbaida Sichuan Biotechnology Co Ltd
Publication of AU2023381502A1 publication Critical patent/AU2023381502A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2023381502A 2022-11-14 2023-11-14 Crystal of substituted piperazine derivative and preparation method therefor Pending AU2023381502A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211417721 2022-11-14
CN202211417721.3 2022-11-14
PCT/CN2023/131627 WO2024104354A1 (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Publications (1)

Publication Number Publication Date
AU2023381502A1 true AU2023381502A1 (en) 2025-05-15

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023381502A Pending AU2023381502A1 (en) 2022-11-14 2023-11-14 Crystal of substituted piperazine derivative and preparation method therefor

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도

Also Published As

Publication number Publication date
CN118027039A (zh) 2024-05-14
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
MX2025005591A (es) 2025-06-02
TWI879228B (zh) 2025-04-01
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
JP2025536416A (ja) 2025-11-05
KR20250086779A (ko) 2025-06-13

Similar Documents

Publication Publication Date Title
EP4269405A1 (en) Preparation and application method of heterocyclic compound as kras inhibitor
TWI557123B (zh) 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
EP3559000B1 (en) Benzimidazole derivatives, preparation methods and uses theirof
US20250270223A1 (en) Crystal of substituted piperazine derivative and preparation method therefor
KR20210105375A (ko) Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
WO2020052627A1 (zh) 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
CA3237756A1 (en) Wee1 protein kinase degradation agent and use thereof
CA2694284A1 (en) Heterocyclic compounds useful as raf kinase inhibitors
CA3107365A1 (en) Pyrazine compounds and uses thereof
EP3741752A1 (en) Tam family kinase /and csf1r kinase inhibitor and use thereof
CN112110938B (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
AU2023201059B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
AU2019394520A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
WO2020224626A1 (zh) 用作激酶抑制剂的化合物及其应用
JP2022517085A (ja) ハロゲン化アリルアミン系化合物及びその適用
CA3179671A1 (en) Kinase inhibitors and uses thereof
AU2019230859B2 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
CA3143813A1 (en) Cdk kinase inhibitor
JP2023535361A (ja) ピリミジン系化合物の塩、結晶形およびその調製方法
CN118632843A (zh) 一种吡啶类衍生物及其用途
CN120787223A (zh) 芳香酰胺类衍生物及其制备方法和用途
CN113264938B (zh) 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用
CN117157284A (zh) Ctla-4小分子降解剂及其应用
HK40104801A (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
HK40103822A (en) Preparation and application method of heterocyclic compound as kras inhibitor